Explore the latest projects funded through our funding platform that aims to speed up the translation of biomedical discoveries into commercially viable diagnostics, devices, therapeutics and tools to improve health and patient care.
A team of Rutgers researchers merged their ideas and technology with the support of research mentors to get the needed funds for developing a novel device capable of detecting the presence of viruses like SARS-CoV-2 in one’s breath.
Tuberculosis is characterized by 10 million cases and 1.5 million deaths per year. New drugs are needed to reduce treatment duration and to treat drug-resistant infections. We propose a solution based on our preclinical drug lead (JSF-3285) that inhibits the essential ß-ketoacyl synthase and exhibits promising efficacy and safety profiles.
We have identified potent small molecule MIF inhibitors that reduce inflammation-associated cytokines in blood cell and mouse assays, and simultaneously exhibit favorable drug likeness properties including oral availability. They hold promise for the treatment of human inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease.
This project aims to advance nanoparticle-based contrast agents for pre-clinical imaging of tumors in small animals. The project focuses on (i) scaling up contrast agent synthesis, (ii) assembly of a prototype imaging system, and (iii) proof of concept studies to monitor tumor growth and response to therapy.
The prevention of microbial adhesion and biofilm formation on medical device/tissue interfaces is an urgent and unmet need. Thi surface functionalization technology, which is specifically effective in preventing biofilm formation on medical devices, such as implants, aims to address this critical healthcare problem.
The research team is developing a Cryptococcus fungal vaccine (HK-fbp1) that has shown cross protection against multiple major invasive mycoses, including Cryptococcus species, Aspergillus fumigatus, and Candida albicans. Its protection remains effective against Cryptococcus and Aspergillus in certain immunocompromised hosts, such as CD4 T cell-depleted mice, a condition mimicking AIDS patients.
Aberrant expression of bone morphogenetic proteins (BMP) has been shown to promote age-related diseases including cancer and Alzheimer’s disease. The research group has developed small molecular inhibitors targeting a BMP receptor that has never been targeted before, aiming to develop this novel class of compounds into a drug for the treatment of cancer and Alzheimer’s disease.
A team of Rutgers researchers merged their ideas and technology with the support of research mentors to get the needed funds for developing a novel device capable of detecting the presence of viruses like SARS-CoV-2 in one’s breath.
The team is developing a novel, first-in-class, orally-available drugs efficacious against tuberculosis and non-tuberculous mycobacterial lung infections. The candidates, RifaAAPs, are active against drug-susceptible, drug-resistant, multi-drug-resistant, and extensively-drug-resistant strains, have lower resistance emergence than current drugs, have higher sterilizing activity than current drugs, and have additive activity in combination with current drugs.
Globally, there are 800,000 new cases of hepatocellular carcinoma (HCC) per year. Treatments are marginally effective today. The team developed a CD147-CAR-NK-based immunotherapy for HCC by re-engineering NK cells to target the specific HCC cell marker CD147, and thereby kill the HCC effectively and safely.